"name","instanceType","label","rationale","uuid:ID","id","description"
"Study Design 1","StudyDesign","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","4cd1d38f-c119-41c6-94b6-d57d3fce294d","StudyDesign_1","The main design for the study"
